Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Understanding lipodystrophy among people living with HIV, including hard belly and visceral fat.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
I know it won’t solve all my lipodystrophy challenges, but I’m feeling desperate to improve my body. Do you relate?
Taking Egrifta and getting CoolSculpt: Is this a midlife crisis or a healthy reality?
There are various options for treating the symptoms of lipodystrophy, both in terms of fat buildup and fat loss.
Many people living with HIV may find they gain a strange type of weight.
The drug Egrifta (tesamorelin), developed as a treatment for excess abdominal fat in people with HIV, may have an additional benefit of promot...
The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV.
Older medications are more likely to cause this change in the body.
Theratechnologies has announced a major shortage of its drug Egrifta (tesamorelin, for injection), which reduces HIV-related excess belly fat.
While newer antiretrovirals have reduced the prevalence of lipodystrophy, a significant proportion of the HIV population still suffers from th...
Egrifta (tesamorelin), a drug approved to reduce gut fat accumulation, also reduces cellular inflammation.
The drug development pipeline currently holds very few new meds to suppress HIV. But on other fronts, drugs to help with side effects and coin...
Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially a...
The first of a two-part look at the top treatment news of 2010.
Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.